Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The company might finally become an oncology player.